Neurocrine Biosciences, Inc. (0K6R.L)
USD 98.2
(-7.23%)
USD 98.2
(-7.23%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 258.3 Million USD | 176.26% |
| 2022 | 93.5 Million USD | -78.77% |
| 2021 | 440.4 Million USD | 6.82% |
| 2020 | 412.3 Million USD | 375.55% |
| 2019 | 86.7 Million USD | -77.68% |
| 2018 | 388.49 Million USD | 5.11% |
| 2017 | 369.61 Million USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 7.24 Million USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 108.74 Million USD | 121.24% |
| 2006 | 49.15 Million USD | -8.28% |
| 2005 | 53.59 Million USD | -9.86% |
| 2004 | 59.45 Million USD | 83.08% |
| 2003 | 32.47 Million USD | 515.37% |
| 2002 | 5.27 Million USD | 46.58% |
| 2001 | 3.6 Million USD | 57.69% |
| 2000 | 2.28 Million USD | 8.71% |
| 1999 | 2.1 Million USD | -4.55% |
| 1998 | 2.2 Million USD | 214.29% |
| 1997 | 700 Thousand USD | -12.5% |
| 1996 | 800 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 252.9 Million USD | 0.0% |
| 2024 Q2 | 256.2 Million USD | 0.0% |
| 2024 Q3 | 251.4 Million USD | 0.0% |
| 2023 Q3 | 85.9 Million USD | -3.59% |
| 2023 Q1 | 259.9 Million USD | 177.97% |
| 2023 Q4 | 258.3 Million USD | 200.7% |
| 2023 Q2 | 89.1 Million USD | -65.72% |
| 2023 FY | 258.3 Million USD | 176.26% |
| 2022 Q2 | 268.6 Million USD | -44.06% |
| 2022 Q4 | 93.5 Million USD | -3.21% |
| 2022 Q1 | 480.2 Million USD | 9.04% |
| 2022 FY | 93.5 Million USD | -78.77% |
| 2022 Q3 | 96.6 Million USD | -64.04% |
| 2021 FY | 440.4 Million USD | 6.82% |
| 2021 Q1 | 429.5 Million USD | 4.17% |
| 2021 Q2 | 435.3 Million USD | 1.35% |
| 2021 Q3 | 437.1 Million USD | 0.41% |
| 2021 Q4 | 440.4 Million USD | 0.75% |
| 2020 Q4 | 412.3 Million USD | 396.75% |
| 2020 FY | 412.3 Million USD | 375.55% |
| 2020 Q3 | 83 Million USD | -1.54% |
| 2020 Q2 | 84.3 Million USD | -83.13% |
| 2020 Q1 | 499.7 Million USD | 476.36% |
| 2019 Q1 | 460.58 Million USD | 18.56% |
| 2019 Q2 | 464.65 Million USD | 0.88% |
| 2019 Q3 | 478.07 Million USD | 2.89% |
| 2019 Q4 | 86.7 Million USD | -81.86% |
| 2019 FY | 86.7 Million USD | -77.68% |
| 2018 Q4 | 388.49 Million USD | 1.26% |
| 2018 Q1 | 374.2 Million USD | 1.24% |
| 2018 Q2 | 378.88 Million USD | 1.25% |
| 2018 Q3 | 383.64 Million USD | 1.26% |
| 2018 FY | 388.49 Million USD | 5.11% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 369.61 Million USD | 1.23% |
| 2017 Q3 | 365.11 Million USD | 1.23% |
| 2017 Q2 | 360.68 Million USD | 0.0% |
| 2017 FY | 369.61 Million USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q1 | 6.16 Million USD | -14.89% |
| 2010 FY | - USD | -100.0% |
| 2010 Q4 | - USD | -100.0% |
| 2010 Q3 | 4.48 Million USD | -11.9% |
| 2010 Q2 | 5.09 Million USD | -17.36% |
| 2009 Q4 | 7.24 Million USD | -13.57% |
| 2009 Q2 | 2.75 Million USD | -8.82% |
| 2009 FY | 7.24 Million USD | 0.0% |
| 2009 Q1 | 3.01 Million USD | 0.0% |
| 2009 Q3 | 8.37 Million USD | 204.65% |
| 2008 Q3 | 108.74 Million USD | 0.0% |
| 2008 FY | - USD | -100.0% |
| 2008 Q1 | 108.74 Million USD | 0.0% |
| 2008 Q2 | 108.74 Million USD | 0.0% |
| 2008 Q4 | - USD | -100.0% |
| 2007 Q4 | 108.74 Million USD | 129.24% |
| 2007 FY | 108.74 Million USD | 121.24% |
| 2007 Q3 | 47.43 Million USD | -1.03% |
| 2007 Q2 | 47.93 Million USD | -1.22% |
| 2007 Q1 | 48.52 Million USD | -1.27% |
| 2006 Q2 | 51.2 Million USD | -2.29% |
| 2006 FY | 49.15 Million USD | -8.28% |
| 2006 Q4 | 49.15 Million USD | -1.95% |
| 2006 Q1 | 52.4 Million USD | -2.21% |
| 2006 Q3 | 50.12 Million USD | -2.1% |
| 2005 Q3 | 54.94 Million USD | -2.59% |
| 2005 FY | 53.59 Million USD | -9.86% |
| 2005 Q1 | 57.95 Million USD | -2.53% |
| 2005 Q2 | 56.4 Million USD | -2.67% |
| 2005 Q4 | 53.59 Million USD | -2.46% |
| 2004 Q1 | 43.09 Million USD | 32.71% |
| 2004 Q3 | 63.94 Million USD | 16.41% |
| 2004 Q2 | 54.93 Million USD | 27.47% |
| 2004 Q4 | 59.45 Million USD | -7.03% |
| 2004 FY | 59.45 Million USD | 83.08% |
| 2003 FY | 32.47 Million USD | 515.37% |
| 2003 Q3 | 19.1 Million USD | -0.09% |
| 2003 Q2 | 19.12 Million USD | 256.57% |
| 2003 Q1 | 5.36 Million USD | 1.63% |
| 2003 Q4 | 32.47 Million USD | 69.97% |
| 2002 FY | 5.27 Million USD | 46.58% |
| 2002 Q3 | 4.47 Million USD | 23.05% |
| 2002 Q4 | 5.27 Million USD | 17.97% |
| 2002 Q2 | 3.63 Million USD | 12.61% |
| 2002 Q1 | 3.22 Million USD | -10.33% |
| 2001 Q4 | 3.6 Million USD | 76.3% |
| 2001 FY | 3.6 Million USD | 57.69% |
| 2001 Q1 | 1.97 Million USD | -13.45% |
| 2001 Q2 | 2.42 Million USD | 22.62% |
| 2001 Q3 | 2.04 Million USD | -15.72% |
| 2000 FY | 2.28 Million USD | 8.71% |
| 2000 Q1 | 1.88 Million USD | -10.29% |
| 2000 Q2 | 1.62 Million USD | -13.64% |
| 2000 Q3 | 1.91 Million USD | 17.39% |
| 2000 Q4 | 2.28 Million USD | 19.53% |
| 1999 Q1 | 2.1 Million USD | -4.55% |
| 1999 Q2 | 2.3 Million USD | 9.52% |
| 1999 Q3 | 2.2 Million USD | -4.35% |
| 1999 Q4 | 2.1 Million USD | -4.55% |
| 1999 FY | 2.1 Million USD | -4.55% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q4 | 2.2 Million USD | 0.0% |
| 1998 Q1 | - USD | -100.0% |
| 1998 FY | 2.2 Million USD | 214.29% |
| 1998 Q3 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q4 | 700 Thousand USD | 0.0% |
| 1997 Q1 | - USD | -100.0% |
| 1997 FY | 700 Thousand USD | -12.5% |
| 1997 Q3 | - USD | 0.0% |
| 1996 Q4 | 800 Thousand USD | 0.0% |
| 1996 Q2 | - USD | -100.0% |
| 1996 Q1 | 1.4 Million USD | 0.0% |
| 1996 FY | 800 Thousand USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -98.593% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -353.253% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 33.403% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -465.294% |
| bluebird bio, Inc. | 224.41 Million USD | -15.097% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -596.621% |
| Imunon, Inc. | 1.13 Million USD | -22571.955% |
| Editas Medicine, Inc. | 24.37 Million USD | -959.823% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 98.006% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 86.925% |
| Myriad Genetics, Inc. | 130.9 Million USD | -97.326% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -678.106% |
| Verastem, Inc. | 40.08 Million USD | -544.365% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 96.789% |
| Waters Corporation | 2.3 Billion USD | 88.796% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.175% |
| Biogen Inc. | 7.18 Billion USD | 96.407% |
| Nektar Therapeutics | 112.62 Million USD | -129.345% |
| Perrigo Company plc | 3.63 Billion USD | 92.89% |
| Dynavax Technologies Corporation | 252.41 Million USD | -2.33% |
| Illumina, Inc. | 1.48 Billion USD | 82.653% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -7875.592% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -25730.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -48.659% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -997.328% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 56.449% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -670.7% |
| Evolus, Inc. | 120.35 Million USD | -114.608% |
| Adicet Bio, Inc. | 17.7 Million USD | -1359.075% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -8302.733% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 90.444% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 48.499% |
| FibroGen, Inc. | 89.69 Million USD | -187.969% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 90.556% |
| OPKO Health, Inc. | 222.03 Million USD | -16.334% |
| Homology Medicines, Inc. | 43.17 Million USD | -498.249% |
| Geron Corporation | 35.05 Million USD | -636.926% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 88.976% |
| Exelixis, Inc. | 189.94 Million USD | -35.987% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -27496.154% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -166.985% |
| Zoetis Inc. | 6.56 Billion USD | 96.065% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -45.055% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -5767.787% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 64.358% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -655.484% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 81.555% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 77.192% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 82.771% |
| Blueprint Medicines Corporation | 610.96 Million USD | 57.722% |
| Insmed Incorporated | 1.19 Billion USD | 78.355% |
| TG Therapeutics, Inc. | 100.11 Million USD | -157.996% |
| Incyte Corporation | 29.16 Million USD | -785.742% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 42.15% |